We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Biologic Imaging Reagents Market To Double

By HospiMedica International staff writers
Posted on 22 Jan 2009
According to a new technical market research report, the global market for biologic imaging reagent technology is expected to be worth US$5.8 billion in 2008. More...
This will increase to over $9.5 billion in 2013, for a compound annual growth rate (CAGR) of 10.2%.

The market report, from BCC Research (Wellesley, MA, USA), is broken down into contrast reagents, optical reagents, and nuclear reagents. Of these, contrast reagents have the largest share of the market, worth an estimated $2.6 billion in 2008. This should increase to $3.7 billion in 2013, for a CAGR of 7.2%.

Nuclear reagents have the second largest market share, generating an estimated $2.1 billion in 2008. This is expected to increase at a CAGR of 12.5% to reach $3.7 billion in 2013. The third largest share of the market belongs to optical reagents, with sales of over $1.2 billion in 2008. This should reach $2.1 billion in 2013, for a CAGR of 12.1%.

Biologic imaging reagents play a fundamental role in current medical, pharmaceutical, and biotechnology industries. Optical imaging reagents allow life sciences researchers and drug developers to visualize and detect biologic processes at the molecular level and to perform key genomics, proteomics and cellular analysis assays. Nuclear and contrast reagents provide important diagnostic information to physicians, enabling the early detection and treatment of disease conditions in cardiology, neurology and oncology.

Technology and market forces are creating a key shift in biologic imaging reagents toward highly specific, multifunctional reagents, according to BBC Research analysts. This shift is creating opportunities for reagent manufacturers to address strategic market opportunities in genomics, proteomics, live cell imaging, early detection of cancers and neurological disorders, drug development, and hybrid imaging/therapeutic reagents.

A main competitive strategy for achieving success in biologic imaging reagents businesses has been acquiring unique technology in fluorescent proteins, fluorescence dyes and probes, quantum dots, and nanotechnology. A second route to gaining technologic competitive advantage is through strategic industry alliances.

BCC Research is a publisher of market research reports and technical publications.

Related Links:

BCC Research



Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Ultrasound System
FUTUS LE
Medical Monitor
SILENIO D
Silver Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.